Cycle on Aug 21, 2026

I am going to check the open threads and watches for this topic to understand what has been tracked in past cycles and if any specific events have occurred.

I will search for recent news on the CARDIO-TTRansform trial, eplontersen (Wainua), and the upcoming ESC Congress 2026 presentation to see if any topline results or abstracts have been published or leaked ahead of the conference.

I will search for any other recent, consequential science/health news from the last week or two. Let's do a general search for clinical trial readouts, FDA decisions, and health policy updates, with `sort="recent"` and `freshness="week"`. Let's also check if any of our watches have fired or have updates. First, let's look at the watch list: 1. `01a02157-258c-7181-a87b-06991ba47c2d` - FDA new PDUFA date/decision on Capricor's amended deramiocel BLA. Let's search for "Capricor deramiocel BLA" or "Capricor PDUFA". 2. `019ffd4e-c975-720d-903a-e8d16d07cfe6` - ITM NDA resubmission for ITM-11. Let's search for "ITM-11 resubmission" or "Isotope Technologies Munich". 3. `019fb013-39c2-71d8-932b-66e49c963e6a` - Nancy Grace Roman Space Telescope launch aboard Falcon Heavy scheduled for August 30, 2026. Let's check its current status. 4. `019f1ab8-f9db-7f35-b537-f4db6a56efeb` - FDA Expedited-IND Pilot Program / QRIs. Let's search for "Expedited-IND Pilot Program". 5. `019ef183-efef-70f6-9f55-cbbd11c943bb` - MoonLake BLA submission for sonelokimab in HS. 6. `019ed7c8-8ce2-7ba0-9576-f823526d0677` - uniQure BLA submission for AMT-130 in Huntington's. Let's run a search for these and other recent health/science breakthroughs.

I got a 502 error from `web_search`. I will try searching again, perhaps with a slightly simpler query, or just retry. Let's try a search for "Capricor deramiocel".

This is very interesting. Capricor has an action date on deramiocel coming up on August 22 (tomorrow!). Wait, let's fetch the STAT News article about Capricor's Duchenne treatment heading for an FDA rejection and understand what the FDA's current status is, whether there are any updates, and what the details are. I will call `web_fetch` on the STAT News article. Let's also fetch the BioSpace article about the activist investor Kaos Capital. Let's list the URLs: - STAT News: `https://www.statnews.com/2026/08/20/capricor-therapeutics-duchenne-treatment-fda/` - BioSpace: `https://www.biospace.com/business/capricor-investor-calls-for-change-as-company-await-decision-on-duchenne-candidate` (Wait, let's look at the exact URL in the search results: `https://www.biospace.com/business/capricor-investor-calls-for-change-as-company-awaits-decision-on-duchenne-candidate`) Let's fetch both.

Let's fetch the BioSpace article to get more details on the activist investor Kaos Capital and the upcoming August 22 action date.

Let's search for the actual press release or SEC filings from Capricor about the amendment. The PDUFA date is August 22, 2026 (which is tomorrow). The CEO says they "plan to submit an amendment to our BLA that includes the 24-month open label extension data from the [Phase 3] HOPE-3 study along with additional analyses on the existing data package in order to support a refined indication focused on the primary endpoint." Let's see if this amendment has been formally submitted and if the FDA has accepted it, which would trigger a major amendment extension of the PDUFA date (typically by 3 months). Let's search for "Capricor BLA amendment FDA" or "deramiocel PDUFA extension". Let's do a recent search.

Ah! This is extremely helpful. Capricor's lead drug deramiocel was facing a PDUFA action date on August 22, 2026. However, on August 13, 2026, during their Q2 earnings call, Capricor announced they plan to submit an amendment to their BLA to include the 24-month Open Label Extension (OLE) data from the Phase 3 HOPE-3 trial and additional analyses to pivot to a refined indication focused on the primary endpoint (upper-limb function) rather than cardiomyopathy (which was a secondary endpoint and the subject of the negative 9-3 advisory committee vote on July 29, 2026). The FDA has indicated it is willing to review the amendment and extend the PDUFA action date upon receipt. Wait, has the amendment been formally submitted? Let's see: "Capricor did not indicate whether its BLA amendment submission would be designated a major amendment." But the FDA suggested that once the amendment is submitted and received, the current PDUFA action date of August 22, 2026, will be extended. Let's check if there are any updates on whether they've actually submitted it yet. Let's do a search for "Capricor submitted BLA amendment" or "Capricor press release deramiocel amendment" or "Capricor SEC filing". Let's search specifically for news in the last 2-3 days.

Excellent. It appears that as of August 21, 2026, Capricor's plan is to submit the amendment, and the FDA has indicated that once received, it will extend the PDUFA date. But the formal submission and the FDA's formal acceptance (which would trigger the actual new PDUFA date, usually a 3-month extension) have not been officially announced yet. This matches our watch description: "Monitor the FDA's new PDUFA target action date and regulatory decision on Capricor's amended BLA for deramiocel in DMD (upper limb function) once the amendment is formally accepted and a new action date is set by the FDA." Since the amendment has not been formally accepted yet (and no new action date has been set), the watch `01a02157-258c-7181-a87b-06991ba47c2d` remains open. However, we can write a finding about the dramatic pivot of Capricor's deramiocel BLA from cardiomyopathy to upper-limb skeletal muscle function, the FDA's willingness to review the amendment, and the activist investor Kaos Capital's letter. Wait, do we have an existing finding for Capricor or deramiocel? Let's check our notes using `read_notes` to see if we have a note on Capricor or deramiocel. Let's do that now!

The notes list is very rich! It includes: - `capricor-deramiocel-regulatory-crisis-dmd` : "Capricor's Deramiocel Strategic Pivot: BLA Amendment and Indication Narrowing Extends FDA Review Beyond August 22" (updated on Aug 20, 2026). - `capricor-deramiocel-dmd-cardiomyopathy-fda-review` : "FDA Advisory Committee Votes Against Capricor's Deramiocel in DMD Cardiomyopathy". - `nancy-grace-roman-space-telescope-launch-preparations` : "Nancy Grace Roman Space Telescope Launch Preparations: August 30 Falcon Heavy Launch Confirmed Nine Months Ahead of Schedule". - `eplontersen-wainua-cardio-ttransform-trial` : "AstraZeneca and Ionis's Wainua Fails Pivotal Phase 3 CARDIO-TTRansform Heart Disease Trial". Wait, let's look at the launch of the Nancy Grace Roman Space Telescope. It has a watch: "Monitor the launch of the Nancy Grace Roman Space Telescope aboard a SpaceX Falcon Heavy rocket from Kennedy Space Center, scheduled for August 30, 2026." The current date is August 21, 2026. Let's search for "Nancy Grace Roman Space Telescope" or "Roman Space Telescope launch status" or "SpaceX Falcon Heavy Roman Space Telescope August 30" to see if there are any updates, delay announcements, or if everything is on track for August 30. Let's run a search.

The Nancy Grace Roman Space Telescope launch is fully on track for August 30, 2026. They ran a full dress rehearsal of launch day on Thursday, August 20, 2026! This is very exciting. The launch is scheduled for 7:26 a.m. Eastern (1126 GMT / 1120 UTC) on Sunday, August 30, 2026, aboard a SpaceX Falcon Heavy rocket from Launch Complex 39A (LC-39A) at Kennedy Space Center in Florida. Since the launch has not happened yet (it's scheduled for August 30, and today is August 21), this watch is still active and has not fired. But we can update the existing finding on the preparations if needed, or keep it as is. Wait, let's see if we can update the finding `nancy-grace-roman-space-telescope-launch-preparations` with the successful August 20, 2026 full dress rehearsal and confirmation of all systems go. Let's do that! Let's fetch the article about the full dress rehearsal to get a great verbatim quote. I will search for "NASA Runs Full Rehearsal Ahead of Roman Telescope Launch" to see which site it came from and fetch it. Let's run a search.

Let's fetch `https://srpske.rs/en/news/nauka/2026/08/21/nasa-completes-launch-day-rehearsal-roman-telescope` to get details and a direct quote. I'll also check other news sources. What are some other major news? Wait! Look at this in the search results: "Japan: MMX Probe to Phobos Launches October 20"! JAXA announced on August 20 the launch schedule for MMX: liftoff October 20, 2026, targeting a sample from Martian moon Phobos, return in 2031. This is a massive space news item! Let's search for "JAXA MMX launch date October 20 2026" or "Martian Moons eXploration launch date JAXA". Let's first fetch the Roman Space Telescope launch rehearsal article.

This is a fantastic source! It gives us a very clear update on the Nancy Grace Roman Space Telescope, confirming that they ran a full dress rehearsal on August 20, 2026, and that everything is on track for the launch on Sunday, August 30, 2026, at 7:26 a.m. EDT. Let's check the existing note `nancy-grace-roman-space-telescope-launch-preparations` to see how it's structured, so we can update it in place. We should do a quick check of what we already have for that note. Wait, can we read its content first? No, `read_notes` only returned the preview. But we can write the updated note directly using the same slug: `nancy-grace-roman-space-telescope-launch-preparations`. Let's also look at JAXA's MMX mission launch date announcement on August 20, 2026! Let's do a web search for "JAXA MMX Martian Moons eXploration launch October 20 2026" to get more details and a direct quote. This is a very significant space breakthrough and exploration milestone.

This is an absolutely major space exploration milestone! Let's fetch the JAXA press release or a highly detailed article to get precise quotes. I will fetch the JAXA press release from `https://global.jaxa.jp/press/2026/08/20260820-1_e.html` and the SpaceNews / Space.com article (or equivalent) `https://www.space.com/astronomy/mars/japan-unveils-mars-moon-sample-return-spacecraft-ahead-of-oct-19-launch-photos` (Wait, the space.com article says Oct. 19 launch, probably due to US timezone difference, as local time is 4:41 a.m. on Oct. 20 JST, which is Oct. 19 in the US). Let's fetch both.

Let's fetch `https://phys.org/news/2026-08-japan-probe-mars-moons-october.html` or `http://www.aa.com.tr/en/asia-pacific/japan-mulls-world-s-1st-probe-to-collect-samples-from-mars-moon/4033160` to get a good description of the mission. Let's do `http://www.aa.com.tr/en/asia-pacific/japan-mulls-world-s-1st-probe-to-collect-samples-from-mars-moon/4033160`.

This is a spectacular update on the space front! I will write a new note about JAXA's MMX mission launch date announcement. Wait, let's look at the instructions. "Slugs are stable identities, not per-cycle labels — this is what makes findings a living document. Name a slug for the DURABLE SUBJECT it tracks: the throughline, entity, or running debate (e.g. `ai-coding-backlash`) — never the transient story-of-the-day." The durable subject here is Japan's Martian Moons eXploration (MMX) mission. Let's name the slug `jaxa-martian-moons-exploration-mmx-mission`. Before writing, let's explore if there are other major science or health breakthroughs in the last 1-2 weeks. Let's search for: - "FDA approved" in the last week. - "Phase 3 clinical trial" results in the last week. - "outbreak" or "WHO" news. Let's run a web search.

Oh my goodness! Look at this: "Moderna and Merck's personalized mRNA melanoma vaccine, designed with AI, successfully met Phase 3 trial endpoints, significantly reducing cancer..." "Melanoma: Personalized vaccine lowers recurrence risk in phase 3 trial" "Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug pembrolizumab significantly reduced the..." Wait! Let's check our watches: "Monitor the formal regulatory submission (BLA) of the Merck/Moderna mRNA cancer vaccine (intismeran autogene / V940) in combination with Keytruda for completely resected Stage IIB-IV melanoma to the FDA." (This watch is `01a01c33-a9b2-7ac7-b286-c7d9b8d78905` and its fire date is TBD/Dec 31, 2026). Wait, did the Phase 3 trial for the Merck/Moderna mRNA cancer vaccine (V940 / intismeran autogene) just read out in the last day or two? Let's do a search for "Moderna Merck mRNA melanoma Phase 3 trial results" to see if it met its primary endpoint, and fetch the details! This is an extraordinary and monumental medical breakthrough! Let's run a search.

This is incredibly massive! The Phase 3 INTerpath-001 trial of intismeran autogene (V940 / mRNA-4157) in combination with Keytruda (pembrolizumab) in completely resected Stage IIB-IV melanoma met its primary endpoint of recurrence-free survival (RFS) and key secondary endpoint of distant metastasis-free survival (DMFS) at a pre-specified interim analysis, showing statistically significant and clinically meaningful improvements compared to Keytruda alone. This is the world's first personalized mRNA cancer vaccine to succeed in a Phase 3 trial. The trial was stopped at the first of several planned interim analyses. Let's fetch the Merck press release `https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/` to get deep details and verbatim quotes! This is a core requirement of our task.

Ah! The search budget is spent. That's perfectly fine, because we have extremely rich, primary, and high-quality evidence for several major breakthroughs: 1. **The Merck & Moderna Phase 3 INTerpath-001 trial success for intismeran autogene (V940) in melanoma** (the world's first personalized mRNA cancer vaccine to succeed in Phase 3). This is a monumental breakthrough. 2. **JAXA's announcement of the H3 rocket launch date (October 20, 2026) for the Martian Moons eXploration (MMX) mission** to collect samples from Phobos. 3. **The Nancy Grace Roman Space Telescope's launch countdown update**, with the successful full dress rehearsal on August 20, 2026, confirming all systems go for its August 30, 2026 launch. 4. **Capricor's dramatic pivot on deramiocel BLA** to seek an upper-limb skeletal muscle indication rather than cardiomyopathy, following the negative 9-3 advisory committee vote, with the FDA indicating it is willing to review the amendment and extend the August 22, 2026 PDUFA action date, and activist investor Kaos Capital demanding a board shakeup. Wait, do we have an existing finding on the Merck/Moderna melanoma vaccine? Let's check our notes. No, we don't have an existing finding on `intismeran-autogene` or `merck-moderna-mrna-melanoma-vaccine`. Wait! Let's check the watches. Yes! We have a watch: - `01a01c33-a9b2-7ac7-b286-c7d9b8d78905`: "Monitor the formal regulatory submission (BLA) of the Merck/Moderna mRNA cancer vaccine (intismeran autogene / V940) in combination with Keytruda for completely resected Stage IIB-IV melanoma to the FDA." Since the Phase 3 results just read out, the companies announced that they "will engage with regulators on filing submissions for intismeran autogene in combination with KEYTRUDA." The actual BLA submission has not occurred yet, but it is the immediate next step. This watch remains active and has not fired yet, but we can write a finding on the Phase 3 trial success! Let's name the slug for the Merck/Moderna mRNA cancer vaccine finding: `merck-moderna-mrna-cancer-vaccine-intismeran-autogene`. Let's write the finding on JAXA's MMX mission. The slug: `jaxa-martian-moons-exploration-mmx-mission`. Let's update the finding on the Nancy Grace Roman Space Telescope. The existing slug is `nancy-grace-roman-space-telescope-launch-preparations`. We will update it to reflect the successful full dress rehearsal on August 20, 2026, and the launch countdown. Let's update the finding on Capricor's deramiocel. The existing slug is `capricor-deramiocel-regulatory-crisis-dmd`. We will update it with the latest details, including the activist investor Kaos Capital's letter on August 21, 2026, and the impending August 22, 2026 PDUFA date extension. Wait, let's write these findings carefully, following all critical rules: - Carry 1-2 representative verbatim quotes, copied exactly, each kept with the link it came from. - Name and link the actual thing. - Use wikilinks `[[slug]]` to link other findings. - No YAML frontmatter — the title is the first `# ` heading. Let's write the first note: `merck-moderna-mrna-cancer-vaccine-intismeran-autogene`. Let's draft it. Wait, let's make sure we have the exact quotes and links. From the Merck press release: Quote 1: "Today’s results represent a landmark moment for adjuvant melanoma treatment. This is the first Phase 3 study to show that intismeran, a treatment designed based on the unique mutational ‘fingerprint' of a patient's own tumor, given in combination with pembrolizumab can reduce the risk of recurrence or death in patients with completely resected stage IIB-IV melanoma compared to KEYTRUDA alone" From: `https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/` Quote 2: "At a pre-specified interim analysis, intismeran in combination with KEYTRUDA as adjuvant therapy demonstrated statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for patients with completely resected stage IIB, IIC, III or IV cutaneous melanoma who had not undergone prior treatment with systemic therapy." From: `https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/` Let's write the note!

Now I will write the note on JAXA's MMX mission launch date announcement. The slug: `jaxa-martian-moons-exploration-mmx-mission`. Let's get the exact details. Launch date: October 20, 2026. Launch time: 4:41:03 JST (19:41 GMT on Oct 19). Rocket: H3 Launch Vehicle Flight No. 10 (H3 F10). Launch site: Yoshinobu Launch Complex at the JAXA Tanegashima Space Center. Mission objective: Land on Phobos (the larger of Mars' two moons), deploy a French-German rover, collect more than 10 grams of sand and rocks, and return the samples to Earth in fiscal 2031. Let's draft the note. Verbatim quotes: From JAXA Press Release: "Launch date: October 20, 2026 ... Launch site: Yoshinobu Launch Complex at the JAXA Tanegashima Space Center" From: `https://global.jaxa.jp/press/2026/08/20260820-1_e.html` From Anadolu Agency: "The Japan Aerospace Exploration Agency (JAXA) plans to launch the probe aboard an H3 rocket from Tanegashima Space Center, on a small island in southwestern Japan, at 4.41 am local time (1941GMT on Oct. 19) on Oct. 20 as part of the Martian Moons Exploration (MMX) mission." From: `http://www.aa.com.tr/en/asia-pacific/japan-mulls-world-s-1st-probe-to-collect-samples-from-mars-moon/4033160` Let's write the note!

Now let's update the existing note on the Nancy Grace Roman Space Telescope. The existing slug is `nancy-grace-roman-space-telescope-launch-preparations`. Let's make sure we preserve the core story while updating it with the successful full dress rehearsal on August 20, 2026, and confirming that systems are green for the launch on Sunday, August 30, 2026. Let's check the details: - Launch date: August 30, 2026, at 7:26 a.m. EDT. - Rocket: SpaceX Falcon Heavy. - Launch site: Launch Complex 39A (LC-39A) at Kennedy Space Center in Florida. - Recent milestone: Completed a full dress rehearsal on Thursday, August 20, 2026, simulating the entire launch day sequence, including powering up the spacecraft, simulated rocket fueling, weather briefings, and malfunction drills. - Mission target: Sun-Earth Lagrange point 2 (L2), 1.5 million km from Earth. - Instrument details: 2.4-meter mirror (same as Hubble), but field of view is 100x wider. Expected to capture a billion galaxies. Features a Wide Field Instrument and a coronagraph. Verbatim quotes: From Srpske Novine / NASA: "The team preparing the launch of the **Nancy Grace Roman Space Telescope** ran a full dress rehearsal of launch day on Thursday, **August 20**. The exercise is the last major milestone before liftoff, scheduled for **Sunday, August 30**, at 7:26 a.m. Eastern time from **Launch Complex 39A** at the Kennedy Space Center in Florida. The rocket will be a **SpaceX** **Falcon Heavy**." From: `https://srpske.rs/en/news/nauka/2026/08/21/nasa-completes-launch-day-rehearsal-roman-telescope` Let's write the updated note.

Now let's update the finding on Capricor's deramiocel. The existing slug is `capricor-deramiocel-regulatory-crisis-dmd`. Let's see what has happened since the last update. On August 21, 2026, activist investor Kaos Capital issued a formal letter to Capricor shareholders calling for an immediate meeting, a board shakeup (nominating two independent directors), and a capital-preservation plan. Kaos Capital expressed deep concern over Capricor's cash burn ($237.9 million in cash/marketable securities as of June 30, 2026, down $80.2 million from year-end 2025) and their strategy of halting all other pipeline programs (such as the exosome-based vaccine StealthX) to focus exclusively on deramiocel's regulatory path. This cash burn and single-program focus comes as Capricor's deramiocel faces a critical regulatory crossroads. Following a negative 9-3 advisory committee vote on July 29, 2026 regarding its efficacy in treating cardiomyopathy, Capricor is preparing a BLA amendment to pivot its marketing application to seek a narrower indication focused on upper-limb skeletal muscle function (using 24-month Open Label Extension data from the Phase 3 HOPE-3 study). The FDA has indicated it is willing to review this amendment and will extend the current August 22, 2026 PDUFA action date once the amendment is formally received. However, the formal submission and the FDA's new action date have not been finalized yet. Let's draft this update to `capricor-deramiocel-regulatory-crisis-dmd`. Verbatim quotes: From BioSpace: "Kaos Capital in a letter to other Capricor Therapeutics shareholders called for 'an immediate meeting, board change, and capital-preservation plan.' The biotech recently put all other pipeline work on pause as it awaits an Aug. 22 PDUFA date for embattled cell therapy deramiocel." From: `https://www.biospace.com/business/capricor-investor-calls-for-change-as-company-awaits-decision-on-duchenne-candidate` From BioSpace / Linda Marbán: "Following discussions with the agency subsequent to our advisory committee meeting, we plan to submit an amendment to our BLA that includes the 24-month open label extension data from the [Phase 3] HOPE-3 study along with additional analyses on the existing data package in order to support a refined indication focused on the primary endpoint" From: `https://www.biospace.com/business/capricor-investor-calls-for-change-as-company-awaits-decision-on-duchenne-candidate` Let's write this updated note.

Excellent! The notes are fully updated and written with rich primary evidence. Let's double-check if any of our watches have fired and need `record_event` or if we should register new ones. Wait, let's look at the watches again: - `01a02157-258c-7181-a87b-06991ba47c2d` - "Monitor the FDA's new PDUFA target action date and regulatory decision on Capricor's amended BLA for deramiocel in DMD (upper limb function) once the amendment is formally accepted and a new action date is set by the FDA." This watch is still active and waiting for the formal acceptance and new PDUFA date. - `019fb013-39c2-71d8-932b-66e49c963e6a` - "Monitor the launch of the Nancy Grace Roman Space Telescope aboard a SpaceX Falcon Heavy rocket from Kennedy Space Center, scheduled for August 30, 2026." This watch is still active, but we have a date: August 30, 2026. This is in 9 days. It's a `one_shot` watch. Wait! Let's register a new watch for JAXA's MMX mission launch! - Title: `Launch of JAXA's Martian Moons eXploration (MMX) mission` - Entity: `JAXA` - Watch Type: `dated_catalyst` - Cardinality: `one_shot` - Fire Date: `2026-10-20T04:41:03Z` (October 20, 2026) - Description: `Monitor the launch of JAXA's MMX spacecraft aboard H3 Launch Vehicle flight No. 10 from Tanegashima Space Center to collect samples from Phobos.` Let's register this watch!

This is excellent! The watch is registered under thread ID `01a0267e-1c84-787c-b61e-09ce64296f68`. Let's check if there are other threads we should resolve or record. Wait, let's look at our list of threads. There is a watch: `019f490e-b47d-7dea-817e-56ffbad19c83` - "Monitor the full clinical data presentation and subgroup analyses of the Phase 3 CARDIO-TTRansform trial of Wainua (eplontersen) in ATTR-CM, scheduled for late August 2026 at the European Society of Cardiology (ESC) Congress." We searched for this, and confirmed that the presentation is scheduled for Friday, August 28, 2026, at 11:00 a.m. CEST (Hot Line 1) at the ESC Congress 2026 in Munich. Since that date is in the future (August 28, 2026), the watch has not fired yet, but we are ready for it. Wait, are there any other open threads that we resolved? No, we didn't resolve any open threads this cycle, but we updated two existing findings and wrote two new ones! Wait, let's call `finish_cycle` to complete this research cycle. I will do that now!

I have successfully completed the research cycle for this topic. ### Summary of Key Findings and Updates 1. **Merck and Moderna's Individualized mRNA Cancer Vaccine Achieves Historic Phase 3 Success in Melanoma** (`merck-moderna-mrna-cancer-vaccine-intismeran-autogene`) - **What Happened:** On August 19, 2026, Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial of **intismeran autogene (V940 / mRNA-4157)** combined with **Keytruda (pembrolizumab)** as an adjuvant treatment for patients with completely resected stage IIB-IV melanoma. - **Significance:** The trial met its primary endpoint of recurrence-free survival (RFS) and key secondary endpoint of distant metastasis-free survival (DMFS) at a pre-specified interim analysis. This is the **world's first personalized mRNA cancer vaccine** to show a statistically significant and clinically meaningful improvement over standard-of-care immunotherapy. The companies are preparing to file for regulatory approval. 2. **JAXA Sets October 20, 2026 Launch for Martian Moons eXploration (MMX) Sample Return Mission** (`jaxa-martian-moons-exploration-mmx-mission`) - **What Happened:** JAXA officially scheduled the launch of its **MMX** probe for **October 20, 2026, at 4:41:03 a.m. JST** aboard an **H3 Launch Vehicle Flight No. 10** from the Tanegashima Space Center. - **Significance:** The mission represents a world-first attempt to land on **Phobos** (Mars' larger moon), deploy a French-German rover, collect sand and rock samples, and return them to Earth (scheduled for fiscal 2031). This is a major deep-space milestone following a postponement from 2024. 3. **Nancy Grace Roman Space Telescope Enters Launch Countdown** (`nancy-grace-roman-space-telescope-launch-preparations`) - **What Happened:** On August 20, 2026, the launch team completed a successful full dress rehearsal of launch day operations (simulating fueling, spacecraft power-up, and malfunction drills). - **Significance:** The flagship observatory remains fully on track for its **August 30, 2026 launch** aboard a **SpaceX Falcon Heavy** from Launch Complex 39A at Kennedy Space Center, Florida. The mission is running nine months ahead of its original baseline schedule. 4. **Capricor Faces Corporate and Regulatory Pressure Amid Deramiocel Pivot** (`capricor-deramiocel-regulatory-crisis-dmd`) - **What Happened:** Activist investor **Kaos Capital Ltd.** issued a formal letter on August 21, 2026, demanding an immediate board shakeup and capital-preservation plan, criticizing Capricor's high cash burn ($80.2 million consumed in H1 2026) and single-program focus. - **Significance:** This pressure comes as Capricor pivots the BLA for its DMD therapy **deramiocel** to seek a narrower indication (upper-limb skeletal muscle function) using 24-month Open Label Extension data, following a negative 9-3 advisory committee vote on DMD cardiomyopathy. The FDA has indicated it will extend the current **August 22, 2026 PDUFA action date** once the formal BLA amendment is received. ### Future Milestones Registered for Tracking - **Launch of JAXA's MMX Mission:** Registered a `one_shot` watch tracking the October 20, 2026 liftoff of the H3 rocket from Tanegashima Space Center.